



PATENTS
Docket No. 500862001500
Clt Ref: REDC-1511

#11
Statement re
Se. Disc
3/17/03

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on Febyary 19, 2003.

LILIA OLSEN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Dominique P. BRIDON, et al.

Serial No.: 09/657,336

Filing Date: September 7, 2000

For: LONG LASTING FUSION PEPTIDE
INHIBITORS OF VIRAL INFECTION

Examiner: J. Parkin

Group Art Unit: 1648

RECEIVED
MAR 10 2003
TECH CENTER 1600/2000

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned hereby states that the content of the attached papers and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required as a result of this statement, applicants petition for any required relief including

extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due to our **Deposit account no. 03-1952** referencing 500862001500. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: February 19, 2003

By: Michael R. Ward
Michael R. Ward
Registration No. 38,651

Morrison & Foerster LLP
425 Market Street
San Francisco, California
Telephone: (415) 268-6237
Facsimile: (415) 268-7522



1648
Box Seg
JF

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

267

Application Number

09/657,336

Filing Date

September 7, 2000

First Named Inventor

Dominique P. BRIDON

Group Art Unit

1648

Examiner Name

J. Parkin

TECH CENTER 1600

MAR 10 2003
2003

RECEIVED

Attorney Docket No.

500862001500

ENCLOSURES (check all that apply)

Fee Transmittal Form - 1 pg IN
DUPL

Fee Attached

Response to Notice to Comply,
Paper 9 and Amended Election to
Restriction Requirement - 18 pgs
(not including INSERTS)

After Final

Affidavits/declarations

Extension of Time Request - 1 pg

Express Abandonment Request

Information Disclosure Statement

Certified Copy of Priority Document(s)

Response to Missing Parts/
Incomplete Application

Response to Missing Parts
under 37 CFR 1.52 or 1.53

Assignment Papers
(for an Application)

Drawing(s)

Licensing-related Papers

Petition

Petition to Convert to a
Provisional Application

Power of Attorney, Revocation
Change of Correspondence Address

Terminal Disclaimer

Request for Refund

CD, Number of CD(s) _____

Remarks

After Allowance Communication
Group

Appeal Communication to Board of
Appeals and Interferences

Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)

Proprietary Information

Status Letter

Other Enclosure(s) (please identify
below):

RETURN RECEIPT POSTCARD
1. COPY of Notice as required - 1
pg
2. INSERT: Replacement pages to
Specification - pages 4, 5, 23 and
137-170;
3. Sequence List:
Statement in Support - 2 pgs
Paper copy - 164 pgs
CRF - 1 disk

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	MORRISON & FOERSTER LLP 425 Market Street, San Francisco, CA 94105-2842 MICHAEL R. WARD (Reg No. 38,651)
Signature	
Date	February 19, 2003

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on February 19, 2003.

LINDA OLSEN

RECEIVED

MAR 10 2003

09/657,336 TECH CENTER 1600/2900 Application No.: 09/657,3



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: *Applicants are reminded that all sequences governed by 37 CFR 1.821 - 1.825 including those present in Tables or Figures must also refer to the relevant SEQ ID NO.*
Applicant Must Provide:
 - An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
 - An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
 - A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE